Elsevier

The Lancet

Volume 359, Issue 9317, 4 May 2002, Pages 1577-1578
The Lancet

Research Letters
Treatment of hypereosinophilic syndrome with imatinib mesilate

https://doi.org/10.1016/S0140-6736(02)08505-7Get rights and content

Summary

Patients with hypereosinophilic syndrome show persistent eosinophilia without recognised cause. We treated five such patients with 100 mg imatinib mesilate (formerly STI-571) daily; four male patients with normal serum interleukin 5 showed complete haematological responses; a female patient who did not respond had raised serum interleukin-5 concentrations. One patient developed leucopenia after 4 days of treatment; counts returned to normal when treatment was stopped. After 1 month, eosinophilia recurred; with further treatment for 2 days, eosinophil counts again became normal. All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations.

References (5)

There are more references available in the full text version of this article.

Cited by (314)

View all citing articles on Scopus
View full text